Q-omics provides the consensus-scored SEC61B profile across patient tissues and cancer cell-line models. SEC61B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SEC61B is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SEC61B protein abundance shows 23,278 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where SEC61B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC61B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC61B survival associations across molecular data types. SEC61B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC61B RNA expression–survival associations across cancer types. High SEC61B expression shows unfavorable associations in ACC, LIHC, UVM, KIRP and UCS, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SEC61B RNA expression.
This table summarizes SEC61B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SEC61B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC61B shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, LIHC, COAD and BLCA. The KIRC box plot shows higher SEC61B RNA expression in tumor versus normal tissue (log2 FC = +0.700, t-test p < 0.001).
This table shows molecular features associated with SEC61B in patient tissues and cancer cell lines. In patient samples, SEC61B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC61B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
